Second radiation therapy for young patients with diffuse midline glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether giving another round of radiation therapy can help children and young adults whose diffuse midline glioma has progressed after their first treatment. It aims to control the tumor and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse midline glioma, either by imaging or biopsy.
- You are between 1 and 21 years old.
- At least 6 months have passed since your first radiation therapy ended.
- You have fully recovered from the side effects of your first radiation therapy.
- Your tumor has shown signs of growing or your symptoms have worsened.
- You are generally well enough to participate, with a performance status above 50% (with exceptions for motor problems due to the tumor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial is testing a new immunotherapy (nivolumab) for children, teens, and young adults with a specific type of aggressive brain tumor (glioblastoma that has a DNA repair problem). It aims to see if giving this treatment early, right after surgery, can help the immune system fight the tumor.
This trial tests a type of radiation therapy called craniospinal irradiation for children and teenagers newly diagnosed with a specific brain tumor (diffuse midline glioma with H3 histone alteration). The goal is to see if this radiation can help control the tumor.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Hear when a new Diffuse Midline Glioma, H3 K27M-Mutant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.